Esophageal Cancer Clinical Trial

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Summary

This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of RO7502175 when administered as a single agent and in combination with atezolizumab in adult participants with locally advanced or metastatic solid tumors, including non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, triple-negative breast cancer (TNBC), esophageal cancer, gastric cancer, cervical cancer, urothelial carcinoma (UC), clear cell renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Participants will be enrolled in 2 stages: dose escalation and dose expansion.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Life expectancy at least 12 weeks
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Measurable disease according to Response Evaluation criteria in Solid Tumors (RECIST) Version 1.1
Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy
Tumor Specimen availability

Exclusion Criteria:

Pregnant or breastfeeding, or intending to become pregnant during the study or within 5 months after the final dose of study treatment
Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment
Active hepatitis B or C or tuberculosis
Positive test for human immunodeficiency virus (HIV) infection
Acute or chronic active Epstein-Barr virus (EBV) infection at screening
Administration of a live, attenuated vaccine (e.g., FluMist) within 4 weeks before first RO7502175 infusion
Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
Active or history of autoimmune disease
Prior allogeneic stem cell or organ transplantation

Study is for people with:

Esophageal Cancer

Phase:

Phase 1

Estimated Enrollment:

365

Study ID:

NCT05581004

Recruitment Status:

Recruiting

Sponsor:

Genentech, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 3 Locations for this study

See Locations Near You

Florida Cancer Specialists - Sarasota
Sarasota Florida, 34232, United States
Winship Cancer Institute
Atlanta Georgia, 30322, United States
SCRI Tennessee Oncology Nashville
Nashville Tennessee, 37203, United States

How clear is this clinincal trial information?

Study is for people with:

Esophageal Cancer

Phase:

Phase 1

Estimated Enrollment:

365

Study ID:

NCT05581004

Recruitment Status:

Recruiting

Sponsor:


Genentech, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.